Institut Català de la Salut
[Álvarez-Román MT, García S] La Paz University Hospital, Madrid, Spain. [Bonanad S] La Fe University and Polytechnic Hospital, Valencia, Spain. [Herrera C] Reina Sofía General University Hospital, Córdoba, Spain. [Rodríguez López M] Álvaro Cunqueiro University Hospital, Vigo, Spain. [García-Diego DA] Spanish Federation of Haemophilia (FEDHEMO), Spain. [Montoro JB] Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-05-07T07:25:57Z
2025-05-07T07:25:57Z
2025
Gene therapy; Haemophilia B; Patient journey roadmap
Teràpia gènica; Hemofília B; Full de ruta del recorregut del pacient
Terapia genética; Hemofilia B; Hoja de ruta del recorrido del paciente
Background The approval of the first gene therapy for haemophilia B represents a disruptive innovation in its management. Its practical integration into the Spanish national healthcare system presents unique challenges and opportunities, requiring the development of a structured, coordinated and multidisciplinary patient journey roadmap to ensure high-quality patient care and outcomes measurement. Methods A multidisciplinary panel of 10 experts was established. The project involved a literature review, structured questionnaires, individual interviews, practical exercises and validation of results by focus group with nominal group methodology. Results No specific patient journey for haemophilia B or for gene therapy were identified in Spain. Associated changes required for current treatment of haemophilia B were identified and proposals made: 1) selection of candidates to receive gene therapy involves individualised assessment of eligibility criteria by a multidisciplinary committee including additional profiles; 2) providing adequate training on gene therapy to healthcare professionals is a must to ensure quality of care; 3) the generation of a specific informed consent document and processes involving hepatology and psychology are essential, with the patient association playing a crucial role; 4) centres without prior practical experience in gene therapy must adapt specific areas to ensure correct preparation and administration; 5) short- and long-term patient follow-up should incorporate continuous monitoring of the patient's liver health and inclusion in registries for evaluation of outcomes.
This study was sponsored by CSL Behring.
Article
Published version
English
Teràpia genètica; Sang - Coagulació - Trastorns - Tractament; Atenció centrada en el pacient; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Genetic Therapy; DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders, Inherited::Hemophilia B; Other subheadings::Other subheadings::/therapy; HEALTH CARE::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care::Patient-Centered Care; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::terapia genética; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::trastornos de la coagulación sanguínea hereditarios::hemofilia B; Otros calificadores::Otros calificadores::/terapia; ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::atención integral de salud::atención primaria de la salud::atención centrada en el paciente
Elsevier
Rare;3
https://doi.org/10.1016/j.rare.2025.100078
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]